A few days ago I posted an article about the use of certain diabetes medications can increase the risk of pancreatitis. Like so many other studies, other experts have rushed forward to question whether the study results are actually correct.
“The Endocrine Society released today a statement highlighting multiple concerns regarding a recent study published in JAMA Internal Medicine by Singh et al. that suggests that treatment of type 2 diabetes with sitagliptin (Januvia®) – a DPP-4 inhibitor – or exenatide (Byetta®) – a GLP-1 analog – may be associated with an increased risk of developing acute pancreatitis severe enough to require hospitalization, a condition with potentially significant morbidity.”
The Endocrine Society states that the way the study was conducted is flawed. Basically they feel that the study overstates the possibilities of increased risks that using the drugs can have. They feel that most of the increased risks can be attributed to diabetes itself.
You can read the full article here: Full Article